2023 World Conference on Lung Cancer (Posters)-P1.24. TAT3 Predicts Favourable Prognosis in Advanced Non Small Cell Lung Cancer

P1.24. TAT3 Predicts Favourable Prognosis in Advanced Non Small Cell Lung Cancer - PDF(Slides)

Pdf Summary

The study examines the role of the STAT3 molecule in advanced non-small cell lung cancer (NSCLC) and its correlation with immune cells, immune exclusion, immune suppression, immune microenvironment, and tumor hallmark signatures. The analysis was conducted using the TCGA database.<br /><br />The results show that upregulation of STAT3 is associated with longer overall survival in advanced lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). However, the expression of STAT3 in LUAD or LUSC was not related to immune cell infiltration. There were also no significant associations between STAT3 expression and immune exclusion, immune suppression, or immune microenvironment signatures.<br /><br />Further exploration revealed that STAT3 expression was highly correlated with the MYC pathway in LUAD and the PI3K/AKT/mTOR pathway in LUSC. STAT3 was also significantly associated with tumor metabolism in both LUAD and LUSC.<br /><br />In conclusion, STAT3 does not play an anti-tumor immune role in advanced NSCLC but instead has an anti-tumor function. The findings suggest that STAT3 could be a potential prognostic marker in advanced NSCLC and could be targeted for therapeutic intervention. The study was conducted by Xuequan Wang and the corresponding author is available at yantaiquan@126.com. The research was carried out at the Key Laboratory of Radiation Oncology of Taizhou, Taizhou Hospital of Zhejiang Province in China.

Asset Subtitle

Xuequan Wang

Meta Tag

Speaker Xuequan Wang

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

STAT3 molecule

non-small cell lung cancer

immune cells

immune exclusion

immune suppression

tumor hallmark signatures

LUAD

LUSC

MYC pathway

tumor metabolism